ATE557025T1 - Inhibitoren von dipeptidylpeptidase iv auf pyrrolopyridinbasis und verfahren - Google Patents
Inhibitoren von dipeptidylpeptidase iv auf pyrrolopyridinbasis und verfahrenInfo
- Publication number
- ATE557025T1 ATE557025T1 AT06759538T AT06759538T ATE557025T1 AT E557025 T1 ATE557025 T1 AT E557025T1 AT 06759538 T AT06759538 T AT 06759538T AT 06759538 T AT06759538 T AT 06759538T AT E557025 T1 ATE557025 T1 AT E557025T1
- Authority
- AT
- Austria
- Prior art keywords
- dipeptidylpeptidase
- pyrrolopyridine
- methods
- based inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68296805P | 2005-05-20 | 2005-05-20 | |
US11/430,657 US7521557B2 (en) | 2005-05-20 | 2006-05-09 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
PCT/US2006/018185 WO2006127287A2 (en) | 2005-05-20 | 2006-05-11 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE557025T1 true ATE557025T1 (de) | 2012-05-15 |
Family
ID=37074817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06759538T ATE557025T1 (de) | 2005-05-20 | 2006-05-11 | Inhibitoren von dipeptidylpeptidase iv auf pyrrolopyridinbasis und verfahren |
Country Status (20)
Country | Link |
---|---|
US (1) | US7521557B2 (de) |
EP (1) | EP1888589B1 (de) |
JP (1) | JP2008540651A (de) |
KR (1) | KR20080026544A (de) |
AR (1) | AR054193A1 (de) |
AT (1) | ATE557025T1 (de) |
AU (1) | AU2006249497A1 (de) |
BR (1) | BRPI0610138A2 (de) |
CA (1) | CA2609508A1 (de) |
EA (1) | EA200702567A1 (de) |
ES (1) | ES2385497T3 (de) |
GE (1) | GEP20104941B (de) |
IL (1) | IL187304A0 (de) |
MX (1) | MX2007014503A (de) |
MY (1) | MY142252A (de) |
NO (1) | NO20075706L (de) |
NZ (1) | NZ562914A (de) |
PE (1) | PE20070022A1 (de) |
TW (1) | TW200722427A (de) |
WO (1) | WO2006127287A2 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1829867A1 (de) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Gegenüber dem Sigmarezeptor pharmazeutisch aktive Imidazolverbindungen |
US7812027B2 (en) * | 2006-05-16 | 2010-10-12 | Merck Sharp & Dohme Corp. | Substitued [1,2,4]triazolo[1,5-a]pyrazines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
JP2010513531A (ja) * | 2006-12-21 | 2010-04-30 | アボット・ラボラトリーズ | 1−アミノ、3−置換フェニルシクロペンタンカルボン酸エステルの個々の立体異性体の製造および単離方法 |
US8217027B2 (en) * | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
MX2010005095A (es) * | 2007-11-07 | 2010-08-03 | Schering Corp | Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion. |
US8993535B2 (en) | 2009-09-04 | 2015-03-31 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
EP2308847B1 (de) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituierte Pyridine als Inhibitoren der Dipeptidyl Peptidase IV und ihre Anwendung für die Behandlung von Diabetes und verwandten Krankheiten |
US8853212B2 (en) | 2010-02-22 | 2014-10-07 | Merck Sharp & Dohme Corp | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
JP5695800B2 (ja) * | 2011-07-09 | 2015-04-08 | 山東軒竹医薬科技有限公司 | ジペプチジルペプチダーゼ−iv阻害剤の塩の結晶形i、及びその製造方法並びにその応用 |
CA2873295A1 (en) * | 2012-08-24 | 2014-02-27 | F. Hoffmann-La Roche Ag | New bicyclicpyridine derivatives |
MX2017011586A (es) | 2015-03-09 | 2017-10-26 | Intekrin Therapeutics Inc | Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia. |
TWI707852B (zh) * | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
US10377743B2 (en) * | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
MX2019011867A (es) | 2017-04-03 | 2020-01-09 | Coherus Biosciences Inc | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. |
EP4005638A4 (de) | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (de) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
HU198005B (en) | 1984-12-04 | 1989-07-28 | Sandoz Ag | Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
HUT48208A (en) | 1985-10-25 | 1989-05-29 | Sandoz Ag | Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
NO882218L (no) | 1987-05-22 | 1988-11-23 | Squibb & Sons Inc | Fremgangsmaate for fremstilling av fosforholdige hmg-coa reduktase-inhibitorer. |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
EP0680320B1 (de) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
EP0873361B1 (de) | 1995-12-13 | 2006-11-02 | The Regents Of The University Of California | Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
KR19980074060A (ko) | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
EP2574336A1 (de) | 1998-02-02 | 2013-04-03 | Trustees Of Tufts College | Verwendung von Dipeptidylpeptidaseinhibitoren zur Regulierung des Glucosemetabolismus |
WO1999046272A1 (en) | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Serine peptidase modulators |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
KR20010083092A (ko) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
MXPA03003007A (es) | 2000-10-06 | 2003-07-14 | Tanabe Seiyaku Co | Compuesto de anillo de cinco miembros que contiene nitrogeno alifatico. |
MXPA04003553A (es) | 2001-10-18 | 2004-07-22 | Bristol Myers Squibb Co | Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas. |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2005025504A2 (en) | 2003-09-12 | 2005-03-24 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
-
2006
- 2006-05-09 US US11/430,657 patent/US7521557B2/en active Active
- 2006-05-11 KR KR1020077029548A patent/KR20080026544A/ko not_active Application Discontinuation
- 2006-05-11 AT AT06759538T patent/ATE557025T1/de active
- 2006-05-11 CA CA002609508A patent/CA2609508A1/en not_active Abandoned
- 2006-05-11 BR BRPI0610138-0A patent/BRPI0610138A2/pt not_active Application Discontinuation
- 2006-05-11 EP EP06759538A patent/EP1888589B1/de active Active
- 2006-05-11 AU AU2006249497A patent/AU2006249497A1/en not_active Abandoned
- 2006-05-11 MX MX2007014503A patent/MX2007014503A/es not_active Application Discontinuation
- 2006-05-11 EA EA200702567A patent/EA200702567A1/ru unknown
- 2006-05-11 WO PCT/US2006/018185 patent/WO2006127287A2/en active Application Filing
- 2006-05-11 GE GEAP200610443A patent/GEP20104941B/en unknown
- 2006-05-11 ES ES06759538T patent/ES2385497T3/es active Active
- 2006-05-11 NZ NZ562914A patent/NZ562914A/en not_active IP Right Cessation
- 2006-05-11 JP JP2008512357A patent/JP2008540651A/ja active Pending
- 2006-05-19 MY MYPI20062319A patent/MY142252A/en unknown
- 2006-05-19 TW TW095117781A patent/TW200722427A/zh unknown
- 2006-05-19 AR ARP060102063A patent/AR054193A1/es unknown
- 2006-05-22 PE PE2006000540A patent/PE20070022A1/es not_active Application Discontinuation
-
2007
- 2007-11-08 NO NO20075706A patent/NO20075706L/no not_active Application Discontinuation
- 2007-11-11 IL IL187304A patent/IL187304A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
GEP20104941B (en) | 2010-04-12 |
EP1888589B1 (de) | 2012-05-09 |
AR054193A1 (es) | 2007-06-06 |
NZ562914A (en) | 2010-11-26 |
MX2007014503A (es) | 2008-02-07 |
MY142252A (en) | 2010-11-15 |
CA2609508A1 (en) | 2006-11-30 |
EP1888589A2 (de) | 2008-02-20 |
US7521557B2 (en) | 2009-04-21 |
ES2385497T3 (es) | 2012-07-25 |
US20060264457A1 (en) | 2006-11-23 |
JP2008540651A (ja) | 2008-11-20 |
EA200702567A1 (ru) | 2008-06-30 |
KR20080026544A (ko) | 2008-03-25 |
TW200722427A (en) | 2007-06-16 |
WO2006127287A3 (en) | 2007-06-07 |
BRPI0610138A2 (pt) | 2010-06-01 |
PE20070022A1 (es) | 2007-01-18 |
AU2006249497A1 (en) | 2006-11-30 |
IL187304A0 (en) | 2008-04-13 |
WO2006127287A2 (en) | 2006-11-30 |
NO20075706L (no) | 2007-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE557025T1 (de) | Inhibitoren von dipeptidylpeptidase iv auf pyrrolopyridinbasis und verfahren | |
ATE501147T1 (de) | Dipeptidylpeptidase-iv-inhibitoren auf azolopyrimidinbasis und verfahren | |
AT502349A3 (de) | Verfahren zur auswertung von touch-signalen und touch-einheit | |
ATE423121T1 (de) | Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren | |
ATE543816T1 (de) | Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase | |
ATE544758T1 (de) | Carboxamidverbindungen und ihre verwendung als calpain-hemmer | |
ATE500824T1 (de) | Verfahren zur reinigung von trans-(-)-delta9- tetrahydrocannabinol und trans-(+)-delta9- tetrahydrocannabinol | |
ATE398126T1 (de) | Azaindolinhibitoren von mtp und apob | |
DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
DK1898903T3 (da) | Inhibitorer af Akt-aktivitet | |
ATE493421T1 (de) | Neue inhibitoren von chymase | |
DE602006016666D1 (de) | Kommunikationsvorrichtung und Verfahren | |
ATE441641T1 (de) | Isochinolinderivate als inhibitoren von rho- kinase | |
DE602006021318D1 (de) | Insektizidzusammensetzungen und verfahren zur hersn | |
DE602006013492D1 (de) | Verfahren und zwischenprodukte | |
ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
DK2302055T3 (da) | Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler | |
DE602007006479D1 (de) | Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen | |
ITMO20060087A1 (it) | Apparato e metodo di elettrostimolazione | |
DE602006010154D1 (de) | Biometrisches System und biometrisches Verfahren | |
DE602006021461D1 (de) | Koaleszierendes filtrationsmedium und verfahren | |
NO345061B1 (no) | Anvendelse av DPP-IV inhibitorer | |
DE602005014898D1 (de) | Flüssigkeitssensor und Verfahren | |
DE602006021341D1 (de) | Rauchgasnassentschwefelungsvorrichtung und verfahren zur rauchgasnassentschwefelung | |
ATE486859T1 (de) | Verbindungen modulierende thrombopoietinaktivität und verfahren |